» Articles » PMID: 2408336

Enhanced Immunogenicity of the Pre-S Region of Hepatitis B Surface Antigen

Overview
Journal Science
Specialty Science
Date 1985 Jun 7
PMID 2408336
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

The 55 codons upstream of the gene sequence encoding the hepatitis B surface antigen (HBsAg) are called the pre-S(2) region. It has been proposed that polypeptides of high molecular weight that contain the pre-S(2) region should be included in future hepatitis B virus (HBV) vaccines. The pre-S(2) region and the S gene product [25 kilodalton (kD)] together compose a polypeptide of high molecular weight (33 kD). As an initial attempt to determine the relevance of the 33-kD polypeptide to development of an HBV vaccine, the murine immune response to pre-S(2)-encoded determinants as compared to S-encoded determinants on the same polypeptide was examined. The results indicate (i) the pre-S(2) region is significantly more immunogenic than the S region of HBsAg, (ii) the 26 amino acid residues at the NH2-terminus of the 33-kD polypeptide represent a dominant antibody binding site on the pre-S(2) region, (iii) the immune response to the pre-S(2) region is regulated by H-2-linked genes distinct from those that regulate the response to the S region, and (iv) immunization of an S region nonresponder strain with HBV envelope particles that contain both the pre-S(2) and S regions can circumvent nonresponsiveness to the S region.

Citing Articles

Both middle and large envelope proteins can mediate neutralization of hepatitis B virus infectivity by anti-preS2 antibodies: escape by naturally occurring preS2 deletions.

Zhang J, Wang Q, Yuan W, Li J, Yuan Q, Zhang J J Virol. 2024; 98(8):e0192923.

PMID: 39078152 PMC: 11334434. DOI: 10.1128/jvi.01929-23.


Hepatitis B Surface Antigen Isoforms: Their Clinical Implications, Utilisation in Diagnosis, Prevention and New Antiviral Strategies.

Lazarevic I, Banko A, Miljanovic D, Cupic M Pathogens. 2024; 13(1).

PMID: 38251353 PMC: 10818932. DOI: 10.3390/pathogens13010046.


Immune response induced by recombinant pres2/S-protein and a pres2-S-protein fused with a core 18-27 antigen fragment of hepatitis B virus compared to conventional HBV vaccine.

Parizad E, Fooladi A, Sedighian H, Behzadi E, Amani J, Khosravi A Virus Genes. 2023; 59(4):499-514.

PMID: 37140777 DOI: 10.1007/s11262-023-01995-z.


Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial.

Vesikari T, Finn A, Van Damme P, Leroux-Roels I, Leroux-Roels G, Segall N JAMA Netw Open. 2021; 4(10):e2128652.

PMID: 34636914 PMC: 8511978. DOI: 10.1001/jamanetworkopen.2021.28652.


Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.

Whitacre D, Peters C, Sureau C, Nio K, Li F, Su L Hum Vaccin Immunother. 2019; 16(2):251-268.

PMID: 31809638 PMC: 7062423. DOI: 10.1080/21645515.2019.1689745.